Richmond Pharmacology is excited to join the 2026 ACCP Annual Meeting in North Bethesda, Maryland, USA, on 27–29 September 2026.

The meeting theme is “Harnessing Changing Clinical Pharmacology Paradigms to Improve Patient Outcomes”, bringing together clinical pharmacologists, researchers, regulators, and industry leaders to discuss the future of therapeutic development, translational science, and precision medicine.

Representing Richmond Pharmacology:

  • Dr Jörg Taubel, Chief Executive Officer

Our Focus at the Meeting

  • Evolving clinical pharmacology models and emerging therapeutic paradigms
  • Strategies to optimise patient outcomes through precision dosing and PK/PD innovation
  • Regulatory updates affecting drug development and clinical trial design
  • Early‑phase research innovations and translational approaches
  • Collaboration between academia, industry, and global regulatory agencies

Connect With Us

If you are attending the 2026 ACCP Annual Meeting and would like to explore collaboration or development opportunities:

📧 fasteranswers@richmondpharmacology.com

Find out more here: 2026 Annual Meeting Program

Latest news

Richmond supports Beam Therapeutics to make significant step forward in potential one-time gene editing treatment for Alpha-1

March 30, 2026
Beam Therapeutics has announced compelling updated clinical data from its ongoing Phase 1/2 Trial of BEAM-302 as a potential treatment for Alpha-1 Antitrypsin Deficiency (AATD).
Read more

Events

Clinical Trials Innovation Programme

10 - 11 February 2026
Richmond Pharmacology is pleased to attend the Clinical Trials Innovation Programme Conference in Nice, France, 10–11 February 2026.
View event